Seegene Unveils Development of CURECA(TM), Next-Gen Fully Automated PCR Solutions with Custom Adaptations

Seegene, a leading company in molecular diagnostics, has announced the development of CURECA(TM), a cutting-edge fully automated system designed to streamline the entire PCR (Polymerase Chain Reaction) process, from sample preparation to result analysis. This innovative system was showcased during the ESCMID Global 2025 conference held in Vienna, Austria, from April 11 to 15.

The CURECA(TM) system has been engineered for continuous operation, capable of functioning 24 hours a day, seven days a week, without the need for operator intervention. This initiative reflects Seegene's commitment to establishing a new global standard in diagnostics and realizing the vision of 'a world without diseases.'

Currently under development, CURECA(TM) aims to enhance PCR automation within laboratory environments. The system includes two primary components: the Customizable Pre-treatment System (CPS) for sample loading and pre-treatment processes, and the Customizable and Expandable Full Automation (CEFA) which manages nucleic acid extraction, PCR setup, gene amplification, and result analysis.

Historically, the pre-treatment of samples in molecular diagnostics has required meticulous handling of various sample types, such as stool, urine, blood, and sputum, along with sorting different container formats. Traditionally, this process has heavily relied on manual labor from trained laboratory professionals. Seegene intends to lead innovations in automating pre-treatment processes for all PCR sample types through the CPS.

The CPS will automate key steps such as sample sorting, centrifugation, vortexing, and heat treatments. Furthermore, it can operate independently of the full CURECA(TM) system and can be applied to other laboratory testing areas such as hematology, biochemistry, and immunodiagnostics, thereby enhancing its utility in clinical laboratory operations.

The modular design of CURECA(TM) will enable laboratories to configure the system according to their operational needs. By facilitating automation across the entire workflow, the system aims to reduce the risk of human error and enable continuous, high-volume PCR testing around the clock.

During the ESCMID Global 2025 conference, Seegene will present a concept that simulates the entire PCR automation workflow--from sample preparation and pre-treatment to nucleic acid extraction, PCR setup, gene amplification, and result analysis. The presentation will also highlight the system's adaptability to various laboratory environments and testing capacities.

Seegene's CURECA(TM) initiative supports its broader vision of 'a world without diseases.' The company aims to redefine standards in molecular diagnostics by providing a fully automated solution for pre-treatment processes across all sample types, which has been a challenge in the field.

In addition to CURECA(TM), Seegene will showcase its portfolio of syndromic real-time PCR assays at the ESCMID 2025 conference under the theme 'Redefining MDx.' This includes validated test solutions currently employed in diagnostics. Symposium sessions will explore the evolving role of molecular diagnostics in combatting antimicrobial resistance (AMR) and the changing diagnostic needs in the post-COVID-19 era.

With 24 years of experience in research, development, manufacturing, and distribution of syndromic real-time PCR technologies, Seegene has proven its expertise, particularly during the COVID-19 pandemic, supplying over 340 million tests across more than 100 countries. The company's syndromic real-time PCR technology allows for simultaneous testing of multiple pathogens causing similar symptoms in a single tube.

For more information, visit Seegene's website or follow them on LinkedIn.